Our Base case remains at SEK 3 per share.
Redeye acknowledges a milestone with the first patient enrolled in the phase I trial with ROSgard in patients undergoing cardiac surgery. The trial will recruit approximately 12 patients and we expect, in line with the company, a readout in late Q2.
LÄS MER